CellMax Life is a precision cancer blood-testing company providing comprehensive, personalized multi-biomarker technology platforms for genetic cancer risk assessment, early detection and personalized treatment of cancer. CellMax Life's flagship product is CellMax CRC-Protect, a multi-biomarker blood test for early detection of colorectal cancer, which is currently marketed in Taiwan.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/26/16 | $9,000,000 | Series A-1 |
Artiman Ventures Stan Shih | undisclosed |
